Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience.
10.3350/kjhep.2012.18.1.48
- Author:
Sang Seok LEE
1
;
Hyun Sung SHIN
;
Hyung Joon KIM
;
Su Jin LEE
;
Hyun Suk LEE
;
Kyung Hee HYUN
;
Yong Hyun KIM
;
Byoung Woon KWON
;
Jin Hyung HAN
;
Hoon CHOI
;
Bae Hwan KIM
;
Joon Hyuk LEE
;
Ha Yan KANG
;
Hyun Deok SHIN
;
Il Han SONG
Author Information
1. Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. ihsong21@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Survival;
Prognosis;
Treatment;
Tumor staging
- MeSH:
Aged;
Antineoplastic Agents/therapeutic use;
Carcinoma, Hepatocellular/drug therapy/*mortality/surgery;
Catheter Ablation;
Cohort Studies;
Female;
Humans;
Kaplan-Meier Estimate;
Liver Neoplasms/drug therapy/*mortality/surgery;
Male;
Middle Aged;
Neoplasm Staging;
Portal Vein;
Prognosis;
Retrospective Studies;
Severity of Illness Index;
Survival Rate;
Venous Thrombosis/complications;
alpha-Fetoproteins/analysis
- From:The Korean Journal of Hepatology
2012;18(1):48-55
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. METHODS: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. RESULTS: The patients were aged 59+/-10 years (mean+/-SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. CONCLUSIONS: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.
